Fundación Arturo López Pérez (FALP) - PPDS
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garrido, Marcelo
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
MB12-C-01-22, NCT05668650: Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Recruiting
3
174
RoW
Pembrolizumab, Keytruda, Pembrolizumab biosimilar, MB12
Laboratorio Elea Phoenix S.A., Syneos Health
Non Small Cell Lung Cancer Metastatic
08/24
12/24
LEGACY-1, NCT03957031: Gastric Cancer Risk Factors Associated With EU and CELAC Populations

Completed
N/A
1600
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Cancer, Gastric
12/23
12/23
LEGACY-2, NCT04015466: Advanced GC Multi-omic Characterization in EU and CELAC Populations

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garrido, Marcelo
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
MB12-C-01-22, NCT05668650: Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Recruiting
3
174
RoW
Pembrolizumab, Keytruda, Pembrolizumab biosimilar, MB12
Laboratorio Elea Phoenix S.A., Syneos Health
Non Small Cell Lung Cancer Metastatic
08/24
12/24
LEGACY-1, NCT03957031: Gastric Cancer Risk Factors Associated With EU and CELAC Populations

Completed
N/A
1600
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Cancer, Gastric
12/23
12/23
LEGACY-2, NCT04015466: Advanced GC Multi-omic Characterization in EU and CELAC Populations

Completed
N/A
800
Europe, RoW
Fundación para la Investigación del Hospital Clínico de Valencia, Instituto Nacional de Cancerologia de Mexico, Amsterdam UMC, location VUmc, Pontificia Universidad Catolica de Chile, Vall d'Hebron Institute of Oncology, INSTITUTO ALEXANDER FLEMING, Hospital Central del IPS, IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
Gastric Cancer
12/23
12/23

Download Options